
Conference Coverage
3 months ago
How AI Fits Into the Pharmaceutical Supply Chain3 months ago
Why Early RWE Planning Matters for Market AccessLatest Content

Supply Chain Signal: Three Tariff Deadlines Reshaping Pharma Manufacturing

DSCSA Can Trace a Package. It Cannot Tell Whether the Next One Will Arrive.

Q&A: Amy Niles on Patient Access Reform in 2026

Pharma Pulse: Retatrutide's Black Market Problem, CSafe's Mobile App, BMS's Houston Bet

The Role of Artificial Intelligence In Access

Shorts










Podcasts
All News

Across pricing, supply chain, and patient support, the playbooks of pharma commercialization are being rewritten at once for a new era.

Adam Colborn explains why affordability and access aren't the same thing for TrumpRx, and how pharmacy participation gaps can leave patients stuck.

Colborn breaks down why most AMCP members don't see TrumpRx as the lowest price option, and what that means for MFN pricing claims.

The Critical Layer for Pharma's Growing Direct-to-Patient Play
DTP programs are outpacing regulatory guidance. Chander Viswanathan and Shannon Wiley, JD make the case for compliance-by-design infrastructure over reactive fixes.

Bristol Myers Squibb will build a $2.3 billion modular manufacturing campus in Houston, part of a $40 billion five-year US investment pledge.

AMCP's Adam Colborn breaks down survey findings on how health plans and PBMs view the TrumpRx platform.

Dual chokepoint disruptions in the Gulf and Red Sea are pushing shippers toward longer, costlier routes with no resolution in sight.

Gifthealth CEO Chip Parkinson on the factors accelerating direct-to-patient model adoption, and what's next for the channel.

FDA is evaluating small pharmacies' package-level tracing capabilities while extending certain Drug Supply Chain Security Act exemptions to those dispensers through November 2027.

CVS Health is pairing a new Lilly pricing collaboration with a $29 MinuteClinic visit and expanded pharmacist support, disclosed alongside a sharp Q2 earnings beat.

Pharma hub services are evolving as manufacturers navigate specialty therapy growth, digital transformation, vendor transitions, and new models for patient access and support.

In this week's Pharma Pulse, a senior source denies AstraZeneca and Bristol Myers Squibb are in merger talks, Cleveland Clinic and Arrive AI push drone delivery toward pharma's last mile, Kenco's AI rollout signals where 3PL is headed, and TailorMed and WeInfuse team up to expand infusion access.

Cleveland Clinic's new prescription drone delivery program and Arrive AI's planned collaboration with LifeSpan Pharmacy highlight growing interest in drone technology for last-mile logistics.

Kenco has put DeepFabric's AI agents into live production across its 3PL operations, with plans to scale to 20 agents within a year.

Serialization data does more than meet DSCSA rules. See how connected event histories improve recalls, returns and inventory visibility.










